Autonomic Function in Patients With Parkinson’s Disease: From Rest to Exercise

Jeann L. Sabino-Carvalho¹, James P. Fisher² and Lauro C. Vianna¹,³*

¹ NeuroVÁSQ – Integrative Physiology Laboratory, Faculty of Physical Education, University of Brasília, Brasília, Brazil,
² Manaaki Mānawa – The Centre for Heart Research, Department of Physiology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand,³ Graduate Program in Medical Sciences, Faculty of Medicine, University of Brasília, Brasília, Brazil

Parkinson’s disease (PD) is a common neurodegenerative disorder classically characterized by symptoms of motor impairment (e.g., tremor and rigidity), but also presenting with important non-motor impairments. There is evidence for the reduced activity of both the parasympathetic and sympathetic limbs of the autonomic nervous system at rest in PD. Moreover, inappropriate autonomic adjustments accompany exercise, which can lead to inadequate hemodynamic responses, the failure to match the metabolic demands of working skeletal muscle and exercise intolerance. The underlying mechanisms remain unclear, but relevant alterations in several discrete central regions (e.g., dorsal motor nucleus of the vagus nerve, intermediolateral cell column) have been identified. Herein, we critically evaluate the clinically significant and complex associations between the autonomic dysfunction, fatigue and exercise capacity in PD.

Keywords: exercise, dorsal motor nucleus of the vagus nerve, parasympathetic activity, sympathetic activity, blood pressure

INTRODUCTION

Parkinson’s disease (PD) is currently the second most common neurodegenerative disorder (Alves et al., 2008; Rossi et al., 2018) and the worldwide prevalence is growing as age and life expectancy increases (Rossi et al., 2018). The disease is well-characterized by a dysfunction of dopamine-producing neurons in the substantia nigra pars compacta and was first described more than 200 years ago (Parkinson, 2002). This dopamine deficiency leads the classical motor dysfunctions (bradykinesia, rigidity, and resting tremor) featuring the disease (Braak and Braak, 2000). In addition, PD may include several non-motor impairments, including autonomic and cardiovascular dysfunction (Gallagher et al., 2010; Goldstein, 2014; Merola et al., 2018; Sabino-Carvalho et al., 2021). Furthermore, some aspects of the autonomic dysfunction can precede the motor dysfunction by more than a decade (Pont-Sunyer et al., 2015). Therefore, early detection of autonomic dysfunction may allow an early diagnosis (Kaufmann et al., 2004, 2017) and seem to make an important contribution to the PD pathophysiology (Goldstein, 2014; Greene, 2014).

Sympathetic and parasympathetic branches of the autonomic nervous system are crucial for homeostasis control (Billman, 2020) and are essential for ensuring that the appropriate cardiovascular and hemodynamic adjustments to exercise occur, such that the metabolic demands of working skeletal muscle are met. Conversely, autonomic dysfunction is associated with fatigue,
impaired exercise capacity, and poor quality of life in several patient populations, including PD (Chaudhuri and Behan, 2004; Gallagher et al., 2010; Nakamura et al., 2011; Vianna and Fisher, 2019; Pechstein et al., 2020). The present mini-review will critically evaluate the evidence for parasympathetic and sympathetic dysfunction in PD both at rest and during exercise, explore how such autonomic dysfunction may affect exercise capacity, and explore the therapeutic potential of exercise training.

**Parasympathetic Dysfunction in PD**

The parasympathetic preganglionic neurons are situated in the nucleus ambiguous (NA) and dorsal motor nucleus of the vagus nerve (DMV). The axons travel within the vagus nerve (tenth cranial nerve) and synapse at postganglionic neurons, such as those located at the cardiac plexus. While the NA contains vagal preganglionic neurons that inhibit the heart rate (Machado and Brody, 1988), the activity of the DMV vagal preganglionic neurons are responsible for tonic parasympathetic control of ventricular excitability (Machhada et al., 2015). Cardiac autonomic parasympathetic neurotransmission is accomplished through the release of acetylcholine and other substances onto receptors located in atrial and ventricular myocardium, modulating the chronotropic, inotropic and dromotropic properties of the heart (Degeest et al., 1964; Coote, 2013).

In patients with PD, a common pathological hallmark is the presence of Lewy bodies. These abnormal aggregates of α-synuclein protein are widely distributed in the hypothalamus, sympathetic [intermediolateral cell column (IML) and sympathetic ganglia] and parasympathetic centers (DMV, NA, and sacral parasympathetic nuclei), and may disrupt the central components of autonomic reflex arc involved in autonomic regulation (Braak and Braak, 2000; Del Tredici and Braak, 2016; Nakamura et al., 2016; Wang et al., 2020). Human studies and animal models of PD provide quantitative evidence for damage to brainstem parasympathetic neurons and in vagus nerves (Beach et al., 2010; Machhada et al., 2015; Walter et al., 2018). Post mortem studies of patients with PD have shown the presence of α-synuclein protein in the vagus nerve (Beach et al., 2010) and in vivo studies have reported significantly smaller vagus nerve axons in patients with PD (Pelz et al., 2018; Walter et al., 2018). With regards to animal models of PD, a reduced activity of DMV neurons is reported (Machhada et al., 2015). In fact, the DMV has been hypothesized by Braak et al. (2003) as being one of the first areas to be affected during the pathological progression of PD in humans, although this is not a universal finding (Kalaitzakis et al., 2008).

Heart rate variability (HRV) derived estimates of cardiac parasympathetic activity have been observed to be reduced in patients with PD (Kallio et al., 2000; Buob et al., 2010; Sabino-Carvalho et al., 2018; Li et al., 2020) independent of the measurement duration/experimental circumstance. However, this finding is not unanimous (Oka et al., 2011; Kiyono et al., 2012; Vianna et al., 2016). Intriguingly, Alonso et al. (2015) demonstrated that the lower the root mean square of successive differences in N-N intervals (RMSSD, a time domain marker of parasympathetic activity) and the standard deviation of N-N intervals (SDNN, the standard deviation of interbeat intervals), the greater the chances of PD developing during an 18-year follow-up period. However, Alonso's findings should be interpreted with caution, as the measurement duration (i.e., ≥ 5-min) is considered suboptimal for this purpose by the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (i.e., ≥ 2-min) (Task Force, 1996). Altogether, these findings may suggest that aggregates of α-synuclein protein in the brainstem parasympathetic neurons might play a role in HRV alterations observed in patients with PD, however, this possibility remains to be tested.

**Sympathetic Dysfunction in PD**

Sympathetic preganglionic cell bodies are located in the IML of the spinal cord and the preganglionic fibers directed to the heart synapse at the stellate ganglion and upper thoracic ganglia (T1–T5). Postganglionic sympathetic fibers synapse in the heart (at the sinoatrial node, atrioventricular node, atria, and ventricles) and in the vasculature. The sympathetic preganglionic neurons in the IML receive strong excitatory drive from neurons of the rostral ventrolateral medulla (RVLM) (Dampney, 1994). Sympathetic preganglionic neurons at the IML also receive direct excitatory inputs from other regions of the central nervous system including the ventromedial medulla, caudal raphe nuclei, A5 noradrenergic cell group of the caudal ventrolateral pons, and the paraventricular hypothalamic nucleus (Dampney, 1994; Dampney et al., 2003). The sympathetic preganglionic neurotransmission is accomplished by the release of acetylcholine, whereas postganglionic neurons release norepinephrine (and other co-transmitters) onto α- and β-adrenergic receptors modulating both chronotropic and inotropic properties of the heart and the peripheral resistance in the vasculature (Drew and Whiting, 1979).

Orthostatic hypotension (OH) affects approximately 50% of the patients with PD and the prevalence may be higher when considering asymptomatic OH (Palma et al., 2015). Noteworthy, OH is often used as a clinical indicator of sympathetic nervous system dysfunction (Goldstein et al., 2015; Kaufmann et al., 2020; Palma and Kaufmann, 2020). Central lesions in the brainstem are thought to mediate the sympathetic dysfunction in PD (Metzger and Emborg, 2019), as showed by Braak and colleagues through analysis of the regional distribution of α-synuclein immunoreactive structures in the brain of 110 subjects (Braak et al., 2003, 2004; Braak and Del Tredici, 2010). This proposed model suggests that the PD process begins in the lower brainstem in the DMV, as well as in the anterior olfactory structures. Thereafter, the disease rostrally ascends from the DMV through regions of the medulla, pontine tegmentum, midbrain, and basal forebrain, reaching the cerebral cortex. Of note, as PD progresses upward from the brainstem, both the severity of the lesions and clinical manifestations of the PD symptoms increase (Braak et al., 2004). The mechanisms and precise neuronal profile damage responsible for the sympathetic dysregulation are not fully understood. However, studies have indicated that the abnormal aggregates of α-synuclein protein distributed in
the IML and sympathetic ganglia contributes to the sympathetic dysfunction (Braak and Braak, 2000; Del Tredici and Braak, 2016; Nakamura et al., 2016; Wang et al., 2020). Moreover, post mortem analyses of patients with PD also showed a selective loss of C1 and C3 neurons (Gai et al., 1993) providing quantitative evidence for brainstem damage of sympathetic neurons. Cardiac sympathetic denervation and lower norepinephrine spillover are also concomitant with the central lesions in patients with PD (Goldstein et al., 2003; Nakamura et al., 2014).

The microneurography technique provides a valuable tool for direct recording of muscle sympathetic nerve activity (MSNA) in humans (Carter, 2019). Shindo et al. (2003) demonstrated that resting MSNA was similar between patients with PD and control subjects. However, a negative association was observed between MSNA and both age and disease duration in PD, reflecting the impact of PD progression on sympathetic dysfunction (Shindo et al., 2003). Nevertheless, the inherent characteristics of PD (i.e., resting tremor and involuntary movements) makes it challenging to obtain and maintain MSNA recordings in this population, and thus only a few studies have attempted this (Shindo et al., 2003, 2005; Sverrisdóttir et al., 2014) and unfortunately not all compared their results with control subjects (Shindo et al., 2005; Sverrisdóttir et al., 2014). Sympathetic postganglionic neuronal function in the heart has been assessed in PD (Rascol and Schelosky, 2009). A myocardial concentration of metaiodobenzylguanidine (MIBG), a physical analog of noradrenaline that is transported into sympathetic terminals, has been used as a biomarker of cardiac sympathetic denervation in PD. Indeed, abnormal MIBG uptake has been reported in patients with PD both with (Nakamura et al., 2014) and without (Oka et al., 2011) OH. However, the cost and invasiveness of the MIBG technique have limited its use in the experimental assessment of cardiac sympathetic activity. Given this, alternative approaches, such as the analysis HRV, may provide important advancements in our understanding of sympathetic dysfunction in PD.

Despite the fact that most indices derived from HRV primarily reflect vagal function, the joint analysis of the low frequency (LF) component, expressed in normalized units, and the LF/HF ratio, has been suggested to be an acceptable marker of sympathetic modulation (Malliani et al., 1994) although this has been challenged (Parati et al., 2006). In this regard, a decreased LF (Li et al., 2020), LF/HF ratio at rest (Oka et al., 2011; Sabino-Carvalho et al., 2020) and a blunted increase in LF/HF ratio during tilt-table testing (Friedrich et al., 2010), has been identified in patients with PD compared to controls. However, this result is not unanimous, and other studies have not observed LF/HF ratio to be decreased at rest in PD (Bouhaddi et al., 2004; Friedrich et al., 2008; Vianna et al., 2016; Sabino-Carvalho et al., 2018). Notably, in patients with PD and OH both a lower resting LF/HF (Barbic et al., 2007) and a blunted LF/HF increase during an active standing test (Vianna et al., 2016) has been observed. This blunted response was also observed through analysis of the sympathetic component of HRV using symbolic analysis. Whereas, those patients without OH demonstrated only an attenuated response during an active standing test compared to controls (Figure 1, Vianna et al., 2016). Taken together, these data highlight the

![FIGURE 1](https://www.frontiersin.org/articles/10.3389/fphys.2021.626640/full#fig1) | Heart rate and LF/HF ratio in response to active standing in controls and in patients with PD with (PD + OH) and without (PD – OH) orthostatic hypotension (A and B, respectively). Non-variable (0V – a proxy of sympathetic activity, C) and very variable (2V – a proxy of parasympathetic activity, D) category of symbolic dynamics analyses of heart rate variability. *P < 0.05 compared with control group. †P < 0.05 compared with PD – OH group. Mean data from Vianna et al. (2016).
presentation of sympathetic dysfunction in PD and suggest that the co-existence of OH, where a reduced vasoconstriction is thought to be a pathophysiological reason (van Wijnen et al., 2018), indicates a more severe condition.

**Cardiovascular Responses to Exercise**

During exercise, several neural mechanisms work in concert to precisely control cardiovascular and hemodynamic responses (Fisher et al., 2015). In neurodegenerative disorders, such as multiple system atrophy and pure autonomic failure, an abnormal cardiovascular responses to exercise is often observed (Low et al., 2012). These patients commonly have a blunted BP increase during isometric exercise (Khurana and Setty, 1996), and may even demonstrate a marked exercise-induced hypotension during dynamic exercise (Akinola et al., 2001). Considering the importance of the sympathetic contribution to the BP response to exercise, studies have suggested that sympathetic nerve activity is reduced during exercise in these patients (Kachi et al., 1988; Dotson et al., 1990; Donadio et al., 2010). Overall, this scenario is quite similar in PD, especially in those patients with OH (Marshall et al., 1961), where parasympathetic and sympathetic dysfunction together may interact to cause the abnormal cardiovascular responses to exercise.

The first evidence for an attenuated cardiovascular response to exercise in PD was provided in the late 80’s by Sachs et al. (1985), Ludin et al. (1987), and Turkka et al. (1987) who demonstrated a blunted BP increase during isometric handgrip exercise. This finding was recently reproduced in dynamic exercise involving a large muscle mass (Reuter et al., 1999; Werner et al., 2006; DiFrancisco-Donoghue et al., 2009; Kanegusuku et al., 2016), resistance exercise (Miyasato et al., 2018) and isometric handgrip exercise (Sabino-Carvalho et al., 2018). Indeed, an inability to increase sympathetic activity to important compliant regions (i.e., splanchic circulation), may impair the blood flow redistribution to the contracting muscles during exercise in PD (Sabino-Carvalho and Vianna, 2020) and, therefore, the reduced vasoconstriction in vascular beds will directly affect BP response to exercise. Consequently these impaired responses might contributed to metabolic distress, tissue/brain hypoperfusion, fatigue, cardiac autonomic dysfunction, and an lower exercise capacity, however, this hypothesis remains to be tested (Figure 2).

Sympatho-excitatory mechanisms are activated during exercise (e.g., exercise pressor reflex and central command), where both mechanically and metabolically sensitive sensory fibers provide feedback via the dorsal horn of the spinal cord to brainstem cardiovascular areas in response to mechanical (i.e., mechanoreflex) and metabolic stimuli (i.e., metaboreflex), respectively (Coote et al., 1971; McCloskey and Mitchell, 1972; Teixeira et al., 2020). The latter has a major role in regulating the sympathetically mediated increases in cardiac contractility, stroke volume, heart rate, peripheral resistance and, consequently, BP during exercise (Fisher et al., 2015; Teixeira et al., 2018). Sabino-Carvalho et al. (2018) assessed the contribution of the metabolic component of the exercise pressor reflex on cardiovascular responses to isometric handgrip exercise in patients with PD, using a experimentally approach described in a landmark study by Alam and Smirk (1937). As indicated in Figure 3, following isometric handgrip exercise performed at 40% of maximum voluntary contraction, a period of post-exercise ischemia was applied in the exercising arm to trap the metabolites generated during muscle contraction. The increases in BP were blunted during exercise and during the isolation of muscle metaboreflex in patients with PD when compared to control subjects. Responses to a non-exercise sympatoexcitatory maneuver (i.e., the cold pressor test) did not differ between groups, which suggest no group differences in generalized sympathetic responsiveness. Therefore, this study suggests that attenuated BP responses to exercise observed in PD are partially explained by an altered metaboreflex in regulating the sympathetically mediated cardiovascular responses during exercise. However, this response does not exclude the involvement of a parasympathetic dysfunction in this altered response.

Parasympathetic activation produces negative inotropic, chronotropic and dromotropic effects on the heart (Armour, 2011; Coote, 2013). The activity of the DMV vagal preganglionic neurons is responsible for tonic parasympathetic control of ventricular excitability (Machhada et al., 2015, 2016, 2017). Machhada et al. demonstrated that silencing of DMV vagal preganglionic neurons provide parasympathetic control of left ventricular inotropy (Machhada et al., 2016), and that decreased
activity of DMV provides a neurophysiological basis for the progressive decline of exercise capacity with aging and in disease states (Machhada et al., 2017). By using an insect peptide (allatostatin) to inhibit DMV neurons the authors were able to show a dramatic reduction in exercise capacity. Noteworthy, along with this blunted exercise capacity, peak BP and heart rate during exercise were also blunted with DMV silencing, while DMV optogenetic recruitment enhanced the cardiac contractility and prolonged the exercise capacity (Machhada et al., 2017). Taken together, these results suggest that intact vagal activity generated by the DMV is required for proper cardiovascular adjustment to exercise.

Lowered vagal activity generated by the DMV might play a role in the attenuated cardiovascular responses, as well as, lowered exercise capacity presented by some patients with PD (Kanegusuku et al., 2016; Sabino-Carvalho et al., 2018). In an animal model of PD, Machhada et al. (2015) demonstrated that PD leads to a markedly reduction in DMV activity and this reduced activity led to changes in the electrophysiological properties of the ventricles, with a significantly shorter right ventricular effective refractory period than control animals and a QT prolongation. The attenuation was specifically in older animals (reflecting the PD progression), and that this reduced DMV neuron activity produced similar changes in ventricular excitability to that observed in control animals after DMV inhibition. Therefore, considering that the DMV neurons are affected by the pathological progression of PD (Braak et al., 2003) and intact DMV parasympathetic
activity seems to determine cardiac contractility and exercise capacity, in animal model (Machhada et al., 2017), this raises the hypothesis that DMV vagal preganglionic neurons might be also involved in the blunted cardiovascular responses to exercise, as well as, the exercise capacity observed in patients with PD. However, further studies are needed to explore this hypothesis.

Exercise Training in PD

There is currently no cure for PD, and although the primary resource for symptomatic control is pharmacologic-based, non-pharmacological low-cost approaches, such as exercise training, are being thought of as the universal prescription for PD (Alberts and Rosenfeld, 2020; Lavin et al., 2020). Epidemiologic evidence suggest that moderate to vigorous exercise training might be protective against the developing of PD (Xu et al., 2010) and the growing body of evidence supports the beneficial effects of exercise on both motor (Silva-Batista et al., 2020a) and non-motor (Ganesan et al., 2014) symptoms. Furthermore, positive results regarding exercise training has been shown in PD animal models (Zhou et al., 2017). In addition to these positive effects, exercise has been employed as a coping resource to manage the quality of life (Corcos et al., 2013) and sleep (Silva-Batista et al., 2017), motor function (David et al., 2016; Vieira-Yano et al., 2020; Silva-Batista et al., 2020b), physical capacity (Kelly et al., 2014), fatigue (Santos et al., 2016) of patients with PD, and disease progression in a PD animal model (Zhou et al., 2017). Despite this, exercise training could be a challenging approach in this population, especially in those patients with OH (Roberson et al., 2019; Sabino-Carvalho et al., 2019; Sabino-Carvalho and Vianna, 2020), because of the impaired autonomic function (Goldstein, 2014; Vianna et al., 2016).

CONCLUSION

Optimal autonomic nervous system function is crucial for evoking appropriate cardiovascular and hemodynamic adjustments to exercise. Emerging evidence suggests that cardiac parasympathetic activity may be also a determinant of exercise capacity. In PD, the pathogenesis affects both parasympathetic and sympathetic nerve activity, which in turn seems to mediate the abnormal cardiovascular responses observed during exercise. These findings may be important in the understanding the complexity of the neural control of circulation in patients with PD. Further studies are needed to better understand the pathophysiological underpinnings on the exercise response in PD.

AUTHOR CONTRIBUTIONS

JS-C wrote the first draft of the manuscript. All the authors read and revised it critically for important intellectual content. All authors approved the final version of the manuscript.

FUNDING

The present work was partially funded by a Beverly Petterson Bishop Award for Excellence in Neuroscience from The American Physiological Society awarded to LV and JS-C receives scholarship support from Coordination for the Improvement of Higher Education Personnel (CAPES; Finance Code 001). LV receives research support from the National Council for Scientific and Technological Development (CNPq; grants: 307293/2019-0 and 431740/2018-6 to LV).

REFERENCES

Akinola, A. B., Smith, G. D., Mathias, C. J., Land, J., Watson, L., Puvi-Rajasingham, S., et al. (2001). The metabolic, catecholamine and cardiovascular effects of exercise in human sympathetic denervation. Clin. Auton. Res. 11, 251–257. doi: 10.1007/bf02298957

Alam, M., and Smirk, F. H. (1937). Observations in man upon a blood pressure raising reflex arising from the voluntary muscles. J. Physiol. 89, 372–383. doi: 10.1101/s0002-8703(37)90581-7

Alberts, J. L., and Rosenfeldt, A. B. (2020). The universal prescription for Parkinson’s disease: exercise. J. Parkinsons Dis. 10, S21–S27.

Alonso, A., Huang, X., Mosley, T. H., Heiss, G., and Chen, H. (2015). Heart rate variability and the risk of Parkinson disease: the atherosclerosis risk in communities study. Ann. Neurol. 77, 877–883. doi: 10.1002/ana.24393

Alves, G., Forsaa, E. B., Pedersen, K. F., Dreetz Gjerstad, M., and Larsen, J. P. (2008). Autonomic Function in Parkinson’s Disease. Heart Rhythm. 5(Suppl. 5), 18–32.

Armour, J. A. (2011). Physiology of the intrinsic cardiac nervous system. Heart Rhythm. 8:739. doi: 10.1542/jhrhum.2011.01.033

Barbic, F., Perezo, F., Canesi, M., Gianni, M., Biagiotti, S., Costantino, G., et al. (2007). Early abnormalities of vascular and cardiac autonomic control in Parkinson’s disease without orthostatic hypotension. Hypertension 49, 120–126. doi: 10.1161/01.hyp.0000250939.71343.7c

Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White Iii, C. L., et al. (2010). Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689–702. doi: 10.1007/s00401-010-0664-3

Billman, G. E. (2020). Homeostasis: the underappreciated and far too often ignored central organizing principle of physiology. Front. Physiol. 11:200. doi: 10.3389/fphys.2020.00200

Bouhaddi, M., Vuillier, F., Fortrat, J. O., Cappelle, S., Henriet, M. T., Rumbach, L., et al. (2004). Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson’s disease: involvement of L-dopa therapy. Auton. Neurosci. 116, 30–38. doi: 10.1016/j.autneu.2004.06.009

Braak, H., and Braak, E. (2000). Pathoanatomy of Parkinson’s disease. J. Neurol. 247(Suppl. 2), I113–I110.

Braak, H., and Del Tredici, K. (2010). [Pathophysiology of sporadic Parkinson’s disease]. Fortschr. Neurol. Psychiat. 78(Suppl. 1), S2–S4.

Braak, H., Del Tredici, K., Rüb, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. doi: 10.1016/s0197-4580(02)00065-9

Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., and Del Tredici, K. (2004). Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 318, 121–134. doi: 10.1007/s00441-004-0956-9

Buob, A., Winter, H., Kindermann, M., Becker, G., Möller, J. C., Oertel, W. H., et al. (2010). Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson’s disease. Clin. Res. Cardiol. 99, 701–706. doi: 10.1007/s00392-010-0170-6

Carter, J. R. (2019). Microneurography and sympathetic nerve activity: a decade-
decade journey across 50 years. J. Neurophysiol. 121, 1183–1194. doi: 10.1152/jn.00570.2018

Santos et al. (2016), physical capacity (Kelly et al., 2014), fatigue (Santos et al., 2016) of patients with PD, and disease progression in a PD animal model (Zhou et al., 2017). Despite this, exercise training could be a challenging approach in this population, especially in those patients with OH (Roberson et al., 2019; Sabino-Carvalho et al., 2019; Sabino-Carvalho and Vianna, 2020), because of the impaired autonomic function (Goldstein, 2014; Vianna et al., 2016).
Goldstein, D. S., Holmes, C., Sharabi, Y., and Wu, T. (2015). Survival in synucleinopathies: a prospective cohort study. Neurology 85, 1554–1561. doi: 10.1212/wnl.0000000000002086
Goldstein, D. S., Pechnik, S., Holmes, C., Eldadah, B., and Sharabi, Y. (2003). Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 42, 136–142. doi: 10.1161/01.HYP.000081216.11623.C3
Greene, J. G. (2014). Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson’s disease. Antioxid Redox Signal. 21, 649–667. doi: 10.1089/ars.2014.5859
Kachi, T., Iwase, S., Mano, T., Saito, M., Kunimoto, M., and Sobue, I. (1988). Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology 38, 1091–1094. doi: 10.1212/wnl.38.7.1091
Kaliatzakis, M. E., Graeber, M. B., Gentleman, S. M., and Pearce, R. K. (2008). The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol. Appl. Neurobiol. 34, 284–295. doi: 10.1111/j.1468-6761.2007.00923.x
Kallo, M., Haapaniemi, T., Turkka, J., Suominen, K., Tonolone, U., Sotaniemi, K., et al. (2000). Heart rate variability in patients with untreated Parkinson’s disease. Eur. J. Neurol. 7, 667–672. doi: 10.1046/j.1468-1331.2000.00127.x
Kanehigashuku, H., Silva-Batista, C., Pecana, T., Nieuwboer, A., Silva, N. D. J., Costa, L. A., et al. (2016). Blunted maximal and submaximal responses to cardiopulmonary exercise tests in patients with Parkinson disease. Arch. Phys. Med. Rehabil. 97, 720–725. doi: 10.1016/j.apmr.2015.12.020
Kauffmann, H., Nahm, K., Purohit, D., and Wolfe, D. (2004). Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63, 1093–1095. doi: 10.1212/01.wnl.0000138500.73671.dC
Kauffmann, H., Norcliffe-Kauffman, L., and Palma, J. A. (2020). Baroreflex dysfunction. N. Engl. J. Med. 382, 163–178.
Kauffmann, H., Norcliffe-Kauffman, L., Palma, J. A., Biaggioni, I., Low, P. A., Singer, W., et al. (2017). Natural history of pure autonomic failure: a United States prospective cohort. Ann. Neurol. 81, 287–297. doi: 10.1002/ana.24877
Kelly, N. A., Ford, M. D., Standaert, D. G., Watts, R. L., Bickel, C. S., Moellerling, D. R., et al. (2008). Heart rate variability in patients with untreated Parkinson’s disease. J. Auton. Res. 25, 315–324. doi: 10.1002/jaut.200702008.001273
Khurana, R. K., and Setty, A. (1996). The value of the isometric hand-grip test–studies in various autonomic disorders. Clin. Auton. Res. 6, 211–218. doi: 10.1007/bf02291136
Kiyono, K., Hayano, J., Kwak, S., Watanabe, E., and Yamamoto, Y. (2012). Non-gaussianity of low frequency heart rate variability and sympathetic activation: lack of increases in multiple system atrophy and Parkinson disease. Front. Physiol. 3:34. doi: 10.3389/fphys.2012.00034
Lavin, K. M., Ge, Y., Sealfon, S. C., Nair, V. D., Wilk, K., Meadham, J. S., et al. (2020). Rehabilitative impact of exercise training on human skeletal muscle transcriptional programs in Parkinsonian disease. Front. Physiol. 11:653. doi: 10.3389/fphys.2020.00653
Li, Y., Wang, J., Li, X., Jing, W., Omorodion, I., and Liu, L. (2020). Association between heart rate variability and Parkinson’s disease: a meta-analysis. Curr. Pharm. Des. doi: 10.2174/13816128206666200905122222 [Epub ahead of print]
Low, D. A., Da Nobrega, A. C., and Mathias, C. J. (2012). Exercise-induced hypotension in autonomic disorders. Auton. Neurosci. 171, 68–78. doi: 10.1016/j.jautneu.2012.07.008
Ludin, S. M., Steiger, U. H., and Ludin, H. P. (1987). Autonomic disturbances and cardiovascular reflexes in idiopathic Parkinson’s disease. J. Neuro. 235, 10–15. doi: 10.1007/bf02471929
Machado, B. H., and Brody, M. J. (1988). Role of the nucleus ambiguus in the regulation of heart rate and arterial pressure. Hypertension 11, 602–607. doi: 10.1161/01.hyp.11.6.602
Marchadil, A., Ang, R., Ackland, G. L., Ninkina, N., Buchman, V. L., Lythgoe, M. F., et al. (2015). Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. Heart Rhythm. 12, 2285–2293. doi: 10.1016/j.hrthm.2015.06.005
Machhada, A., Marina, N., Korsak, A., Stuckey, D. J., Lythgoe, M. F., and Gourine, A. V. (2016). Origins of the vagal drive controlling left ventricular contractility. J. Physiol. 594, 4017–4030. doi: 10.1113/jp270984

Machhada, A., Trapp, S., Marina, N., Stephens, R. C. M., Whittle, J., Lythgoe, M. F., et al. (2017). Vagal determinants of exercise capacity. Nat. Commun. 8:50077.

Malliani, A., Lombardi, F., and Pagani, M. (1994). Power spectrum analysis of heart rate variability: a tool to explore neural regulatory mechanisms. Br. Heart J. 71, 1–2. doi: 10.1136/hrt.71.1.1

Marshall, R. J., Schirger, A., and Shepherd, J. T. (1961). Blood pressure during supine exercise in idiopathic orthostatic hypotension. Circulation 24, 76–81. doi: 10.1161/01.cir.24.1.76

McCloskey, D. I., and Mitchell, J. H. (1972). Reflex cardiovascular and respiratory responses originating in exercising muscle. J. Physiol. 224, 173–186. doi: 10.1113/jphysiol.1972.sp009887

Merola, A., Romagnolo, A., Rosso, M., Suri, R., Berndt, Z., Maule, S., et al. (2018). Autonomic dysfunction in Parkinson’s disease: a prospective cohort study. Mov. Disord. 33, 391–397. doi: 10.1002/mds.27268

Metzger, J. M., and Emborg, M. E. (2019). Autonomic dysfunction in Parkinson's disease and animal models. Clin. Auton. Res. 29, 397–414. doi: 10.1007/s10286-018-00584-7

Miyasato, R. S., Silva-Batista, C., Pecanha, T., Low, D. A., De Mello, M. T., Piemonte, M. E. P., et al. (2018). Cardiovascular responses during resistance exercise in patients with Parkinson disease. PM R 10, 1145–1152. doi: 10.1016/j.pmrj.2018.04.009

Nakamura, K., Mori, F., Tanji, K., Miki, Y., Toyoshima, Y., Kakita, A., et al. (2016). α-Synuclein pathology in the cranial and spinal nerves in Lewy body disease. Neuropathology 36, 262–269. doi: 10.1111/neup.12269

Nakamura, T., Hirayama, M., Hara, T., Hama, T., Watanabe, H., and Sobue, G. (2011). Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson’s disease? Mov. Disord. 26, 1869–1874. doi: 10.1002/mds.23744

Nakamura, T., Hirayama, M., Hara, T., Mizutani, Y., Suzuki, J., Watanabe, H., et al. (2014). Role of cardiac sympathetic nerves in preventing orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat. Disord. 20, 409–414. doi: 10.1016/j.parkreldis.2014.01.003

Oka, H., Toyoda, C., Yogo, M., and Mochio, S. (2011). Cardiorespiratory dysautonomia in de novo Parkinson’s disease without orthostatic hypotension. Eur. J. Neurol. 18, 286–292. doi: 10.1111/j.1468-1331.2010.03135.x

Palma, J. A., Gomez-Esteban, J. C., Nordcliff-Kaufmann, L., Martinez, J., Tijero, B., Berganzo, K., et al. (2015). Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov. Disord. 30, 639–645. doi: 10.1002/mds.26079

Palma, J. A., and Kaufmann, H. (2020). Orthostatic hypotension in Parkinson disease. Clin. Geriatr. Med. 36, 53–67. doi: 10.1016/j.cger.2019.09.002

Parat, G., Mancia, G., Di Rienzo, M., and Castiglioni, P. (2006). Point: cardiovascular variability is/is not an index of autonomic control of circulation. J. Appl. Physiol. (1985) 101, 676–678; discussion 681–672.

Parkinson, J. (2002). An essay on the shaking palsy. 1817.

Piemonte, M. E. P., et al. (2020a). A randomized, controlled trial of exercise during exercise: the connectivity of skeletal muscle afferents to the brain. J. Funct. Morphol. Kinesiol. 10, 1145–1152. doi: 10.1016/j.jfmrk.2020.04.009

Piemonte, M. E. P., et al. (2020b). A randomized, controlled trial of exercise during exercise: the connectivity of skeletal muscle afferents to the brain. J. Funct. Morphol. Kinesiol. 10, 1145–1152. doi: 10.1016/j.jfmrk.2020.04.009

Piemonte, M. E. P., et al. (2017). Resistance training improves sleep quality in patients with moderate Parkinson’s disease. J. Strength Cond. Res. 31, 2270–2277. doi: 10.1519/jsc.0000000000001685

Silva-Batista, C., De Brito, L. C., Corcos, D. M., Roschel, H., De Mello, M. T., Piemonte, M. E. P., et al. (2017). Orthostatic hypotension in Parkinson’s disease: a challenging non-motor feature. SAGE Open Med. 71, 37–42. doi: 10.1111/j.1600-0404.1985.tb03164.x

Santos, P. C., Gobbi, L. T., Orcioli-Silva, D., Simieli, L., Van Dieren, J. H., and Barbieri, F. A. (2016). Effects of leg muscle fatigue on gait in patients with Parkinson’s disease and controls with high and low levels of daily physical activity. Gait Posture 47, 86–91. doi: 10.1016/j.gaitpost.2016.04.002

Shindo, K., Kaneko, E., Watanabe, H., Sugimoto, T., Ohta, E., Ohashi, K., et al. (2005). Analysis of the relationship between muscle sympathetic nerve activity and cardiac 123I-metaiodobenzylguanidine uptake in patients with Parkinson’s disease. Mov. Disord. 20, 1419–1424. doi: 10.1002/mds.20580

Shindo, K., Watanabe, H., Tanaka, H., Ohashi, K., Nagasaki, T., Tsunoda, S., et al. (2003). Age and duration related changes in muscle sympathetic nerve activity in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 74, 1407–1411. doi: 10.1136/jnnp.74.10.1407

Silva-Batista, C., De Lima-Pardini, A. C., Nucci, M. P., Coelho, D. B., Batista, A., Piemonte, M. E. P., et al. (2017). Resistance training improves sleep quality in patients with moderate Parkinson’s disease. J. Strength Cond. Res. 31, 2270–2277. doi: 10.1519/jsc.0000000000001685

Silva-Batista, C., De Lima-Pardini, A. C., Nucci, M. P., Coelho, D. B., Batista, A., Piemonte, M. E. P., et al. (2020a). A randomized, controlled trial of exercise for Parkinsonian individuals with freezing of gait. Mov. Disord. 35, 1607–1617. doi: 10.1002/mds.28128

Silva-Batista, C., De Lima-Pardini, A. C., Nucci, M. P., Coelho, D. B., Batista, A., Piemonte, M. E. P., et al. (2020b). A randomized, controlled trial of exercise for Parkinsonian individuals with freezing of gait. Mov. Disord. 35, 1607–1617. doi: 10.1002/mds.28128

Sverrisdottir, Y. B., Green, A. L., Aziz, T. Z., Bahuri, N. F., Hyam, J., Basnayake, S. D., et al. (2014). Differentiated baroreflex modulation of sympathetic nerve activity during deep brain stimulation in humans. J. Neurophysiol. 101, 676–678; discussion 681–672.

Teixeira, A. L., Fernandes, I. A., and Vianna, L. C. (2020). Cardiovascular control during exercise: the connectivity of skeletal muscle afferents to the brain. Exerc. Sport Sci. Rev. 48, 83–91. doi: 10.1249/esr.0000000000000218

Turkla, J. T., Tolonen, U., and Myllyla, V. V. (1987). Cardiovascular reflexes in Parkinson’s disease. Eur. Neurol. 26, 104–112. doi: 10.1159/000116319
van Wijnen, V. K., Harms, M. P. M., and Wieling, W. (2018). Orthostatic hypotension in the first minute after standing up: what is the clinical relevance and do symptoms matter? *Hypertension* 71, 816–818. doi: 10.1161/hypertensionaha.118.10609

Vianna, L. C., and Fisher, J. P. (2019). Reflex control of the cardiovascular system during exercise in disease. *Curr. Opin. Physiol.* 10, 110–117. doi: 10.1016/j.cophys.2019.05.002

Vianna, L. C., Teixeira, A. L., Santos, T. S., Rodrigues, G. D., Bezerra, L. A., Soares, P. P., et al. (2016). Symbolic dynamics of heart rate variability in Parkinson’s disease patients with orthostatic hypotension. *Int. J. Cardiol.* 225, 144–146. doi: 10.1016/j.ijcard.2016.09.091

Vieira-Yano, B., Martini, D. N., Horak, F. B., De Lima-Pardini, A., Almeida, F., Santana, V. P., et al. (2020). The adapted resistance training with instability randomized controlled trial for gait automaticity. *Mov. Disord.* 36, 152–163. doi: 10.1002/mds.28298

Walter, U., Tsiberidou, P., Kersten, M., Storch, A., and Löble, M. (2018). Atrophy of the vagus nerve in Parkinson’s disease revealed by high-resolution ultrasonography. *Front. Neurol.* 9:805. doi: 10.3389/fneur.2018.00805

Wang, X. J., Ma, M. M., Zhou, L. B., Jiang, X. Y., Hao, M. M., Teng, R. K. F., et al. (2020). Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy. *Nat. Commun.* 11:934.

Werner, W. G., Difrancesco-Donoghue, J., and Lamberg, E. M. (2006). Cardiovascular response to treadmill testing in Parkinson disease. *J. Neurol. Phys. Ther.* 30, 68–73. doi: 10.1097/01.npt.0000282570.78544.00

Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blais, A., Schatzkin, A., et al. (2010). Physical activities and future risk of Parkinson disease. *Neurology* 75, 341–348. doi: 10.1212/wnl.0b013e3181ea1597

Zhou, W., Barkow, J. C., and Freed, C. R. (2017). Running wheel exercise reduces alpha-synuclein aggregation and improves motor and cognitive function in a transgenic mouse model of Parkinson’s disease. *PLoS One* 12:e0190160. doi: 10.1371/journal.pone.0190160

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Sabino-Carvalho, Fisher and Vianna. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). No use, distribution or reproduction is permitted which does not comply with these terms.